Hims & Hers Health Inc. HIMS has decided to cease offering its compounded semaglutide pill. Hims & Hers Explains Its Decision ...
Novo Nordisk has sued Hims for allegedly violating patents protecting semaglutide, seeking potentially “hundreds of millions” ...
By Anusha Shah and Amina Niasse Feb 7 (Reuters) - Online telehealth company Hims & Hers on Saturday reversed course on its ...
Novo Nordisk’s CEO says compounded GLP-1 knockoffs sourced from overseas ingredients could endanger patients and undermine ...
Novo Nordisk filed suit in the U.S. District Court for the District of Delaware on February 9, 2026, alleging that compounded semaglutide ...
The agency flagged several violations at a compounding pharmacy owned by Hims & Hers, including “infestation by rodents, ...
FDA enforcement will focus on restricting GLP-1 APIs in mass-marketed, nonapproved compounded products to address unverifiable quality, safety, and efficacy under the FD&C Act. Appropriate compounding ...
Stocktwits on MSN
HIMS stock plunges 10% after hours: FDA chief warns of 'swift action' on copycat drugs after Novo semaglutide knockoff launch
The drop followed a same-day launch of a compounded semaglutide pill that drew FDA warnings and a legal pushback from Novo ...
On Thursday, Hims & Hers Health Inc. (NYSE:HIMS) announced Thursday an expansion of its weight loss specialty by enabling ...
NVO shares jump 3.6% after Hims & Hers halts compounded semaglutide following an FDA warning and patent lawsuit.
The lawsuit comes after Hims & Hers briefly launched a $49 compounded version of Wegovy and abandoned the product following ...
Novo Nordisk, the manufacturer of Wegovy, responded strongly to the initial launch of Hims & Hers’ compounded semaglutide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results